Enfortumab Vedotin-Ejfv: uses, dosing, side effects & brands
Enfortumab Vedotin-Ejfv is a medicine sold in the U.S. under one brand, for urinary bladder neoplasms. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Urinary Bladder Neoplasms
- Available as
- Injectable
- Sold as
- Padcev
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
- Boxed warning
- Boxed warning
How enfortumab vedotin-ejfv is dosed
From the FDA label for Padcev (application BLA761137). Other enfortumab vedotin-ejfv products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
For intravenous infusion only. Do not administer PADCEV as an intravenous push or bolus. Do not mix with, or administer as an infusion with, other medicinal products. ( 2.3 ) • MIBC: The recommended dose of PADCEV in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph is 1.25 mg/kg (up to a maximum dose of 125 mg) given as an intravenous infusion over 30 minutes. For patients who: ○ are eligible for cisplatin-containing chemotherapy, PADCEV is administered as neoadjuvant treatment on Days 1 and 8 of each 21‑day cycle for 4 cycles or until disease progression that precludes curative intent cystectomy or unacceptable toxicity, followed by adjuvant treatment on Days 1 and 8 of each 21-day cycle for 5 cycles or until disease recurrence or unacceptable toxicity, or ○ are ineligible for cisplatin-containing chemotherapy, PADCEV is administered as neoadjuvant treatment on Days 1 and 8 of each 21‑day cycle for 3 cycles or until disease progression that precludes curative intent cystectomy or unacceptable toxicity, followed by adjuvant treatment on Days 1 and 8 of each 21‑day cycle for 6 cycles or until disease recurrence or unacceptable toxicity. ( 2.1 ) • La/mUC: The recommended dose of PADCEV in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph is 1.25 mg/kg (up to a maximum dose of 125 mg) given as an intravenous infusion…
Enfortumab Vedotin-Ejfv side effects
The following serious adverse reactions are described elsewhere in the labeling: • Skin Reactions [see Boxed Warning , Warnings and Precautions ( 5.1 )] • Hyperglycemia [see Warnings and Precautions ( 5.2 )] • Pneumonitis/Interstitial Lung Disease (ILD) [see Warnings and Precautions ( 5.3 )] • Peripheral Neuropathy [see Warnings and Precautions ( 5.4 )] • Ocular Disorders [see Warnings and Precautions ( 5.5 )] • Infusion Site Extravasation [see Warnings and Precautions ( 5.6 )] The most common adverse reactions, including laboratory abnormalities, (≥20%) were: • PADCEV in combination with intravenous pembrolizumab for the treatment of MIBC: decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, rash, increased creatinine, decreased lymphocytes, fatigue, pruritus, decreased sodium, peripheral neuropathy, increased potassium, diarrhea, alopecia, dysgeusia, decreased appetite, nausea, constipation, urinary tract infection, dry eye, increased glucose, decreased weight, decreased potassium, hyperglycemia, decreased phosphate, and decreased neutrophils. ( 6.1 ) • PADCEV in combination with intravenous pembrolizumab for the treatment of la/mUC: increased aspartate aminotransferase, increased creatinine, rash, increased glucose, peripheral neuropathy, increased lipase, decreased lymphocytes, increased alanine aminotransferase, decreased…
Who shouldn’t take enfortumab vedotin-ejfv
None. None. ( 4 )
Enfortumab Vedotin-Ejfv drug interactions
Concomitant use of dual P-gp and strong CYP3A4 inhibitors with PADCEV may increase the exposure to monomethyl auristatin E (MMAE). ( 7.1 ) 7.1 Effects of Other Drugs on PADCEV Dual P-gp and Strong CYP3A4 Inhibitors Concomitant use with dual P-gp and strong CYP3A4 inhibitors may increase unconjugated MMAE exposure [see Clinical Pharmacology ( 12.3 )] , which may increase the incidence or severity of PADCEV toxicities. Closely monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors.
Every enfortumab vedotin-ejfv product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Padcev.
What people report to the FDA about enfortumab vedotin-ejfv
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 254 reports naming enfortumab vedotin-ejfv, and the FDA flagged 95% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- fatigue38 reports
- inappropriate schedule of product administration35 reports
- rash34 reports
- diarrhoea33 reports
- nausea32 reports
- neuropathy peripheral32 reports
- decreased appetite31 reports
- alopecia23 reports
Read these as a signal, not a rate. A report does not mean enfortumab vedotin-ejfv caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related calculators
Frequently asked questions
What is enfortumab vedotin-ejfv?
Padcev (Enfortumab Vedotin-Ejfv) is a medication used to treat Urinary Bladder Neoplasms.
Can you take enfortumab vedotin-ejfv with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run enfortumab vedotin-ejfv against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does enfortumab vedotin-ejfv come in?
Across the brands we track, enfortumab vedotin-ejfv is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic enfortumab vedotin-ejfv?
We do not currently list a generic-labelled enfortumab vedotin-ejfv product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Enfortumab Vedotin-Ejfv: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/enfortumab-vedotin-ejfv
- MLA
- “Enfortumab Vedotin-Ejfv: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/enfortumab-vedotin-ejfv.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for enfortumab vedotin-ejfv on DailyMed (NIH) ↗ — including its boxed warning in full.